knowledgeispower

Roche Covets Genentech for Good Reason

Didn't I read this same article on genomics in early 2000? Or was that an article on SNPs? Or gene therapy?

Roche Covets Genentech for Good Reason

Didn't I read this same article on genomics in early 2000? Or was that an article on SNPs? Or gene therapy?

Medivation's Attitude Warrants a Pullback

1) The mechanism of action IS known. It prevents dysfunction of the mitochondria, which the CEO has detailed in presentations and is available all over the web.
2) It is not available over the counter in Russia, nor is it made anywhere in the world.
3) The FDA has accepted the Phase II as a pivotal trial for approval, and will only require one (rather than two trials) for approval. That is rare, and signifies the Russian Phase II it has passed FDA scrutiny.
4) Financial committment is chump change? You mention the $225 signing fee, but conveniently left out the $500 in milestones and 40% profit split.
3) Failed to deliver on the publication? The Lancet is one of the most prestigous medical publications in the world, with a very rigourous peer review process.
4) If you think the stock is due to consolidate, that is one thing. But iof you know the facts, the fundamentals are better than ever.
5) You clearly don't know this company very well.